164 related articles for article (PubMed ID: 22014215)
21. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
22. [Study of RON mediated invasion of Raji cell line and drug-target effects].
Zhan BC; Dong YH; Fan J; Yao HP; Jin J; Tong XM
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):926-30. PubMed ID: 24294846
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
[TBL] [Abstract][Full Text] [Related]
25. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.
Chen JF; Yu BX; Yu R; Ma L; Lv XY; Cheng Y; Ma Q
Oncol Rep; 2017 Feb; 37(2):721-728. PubMed ID: 28075465
[TBL] [Abstract][Full Text] [Related]
27. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
[TBL] [Abstract][Full Text] [Related]
28. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
29. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
[TBL] [Abstract][Full Text] [Related]
30. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
31. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
[TBL] [Abstract][Full Text] [Related]
32. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells.
Yao HJ; Zhang YG; Sun L; Liu Y
Biomaterials; 2014 Nov; 35(33):9208-23. PubMed ID: 25115788
[TBL] [Abstract][Full Text] [Related]
33. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
Yao HP; Tong XM; Hudson R; Wang MH
J Exp Clin Cancer Res; 2020 Sep; 39(1):198. PubMed ID: 32962738
[TBL] [Abstract][Full Text] [Related]
34. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.
Wang MH; Lee W; Luo YL; Weis MT; Yao HP
J Pathol; 2007 Dec; 213(4):402-11. PubMed ID: 17955509
[TBL] [Abstract][Full Text] [Related]
35. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
[TBL] [Abstract][Full Text] [Related]
36. RON confers lapatinib resistance in HER2-positive breast cancer cells.
Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
[TBL] [Abstract][Full Text] [Related]
37. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
[TBL] [Abstract][Full Text] [Related]
38. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
Yao HP; Hudson R; Wang MH
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
[TBL] [Abstract][Full Text] [Related]
39. Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Yi H; Cho HJ; Cho SM; Jo K; Park JA; Kim NH; Amidon GL; Kim JS; Shin HC
Int J Oncol; 2012 Jul; 41(1):310-6. PubMed ID: 22552503
[TBL] [Abstract][Full Text] [Related]
40. [Altered expressions of embryonic stem-related genes in pancreatic cancer stem cell].
Lu YH; Zhu H; Wang ZW; Fan XJ; Zhu SJ; Li XH; Wang Y; Lu JJ; Zhu MY
Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(44):3107-10. PubMed ID: 22340650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]